Articles tagged with Cancer Medication
The Cancer IO project aims to drive creation of a Finnish IO ecosystem and national IO growth strategy, boosting business competitiveness and individualization of care. With 10 million euros funding, the project will support top-level research and development of cancer immunotherapy treatments.
Menkes disease is a rare genetic disorder caused by a copper deficiency, leading to severe brain damage and neuromuscular deficits. Researchers from Texas A¼M have found promising results using the cancer drug elesclomol to deliver copper to tissues and restore energy production.
A clinical trial found that olanzapine significantly improved patient quality of life by reducing nausea and vomiting scores. The study showed that patients who received olanzapine reported less vomiting, better appetite, and better well-being compared to those who received a placebo.
Researchers identified two previously overlooked genes as potential new therapeutic targets for cancer treatment and male infertility. RMPs play a key role in the RNA modification process, adding or removing chemical groups to the sequence, and altering the original code copied from DNA.
Researchers developed a new conjugated drug, Nav-Gal, that selectively removes senescent cells, minimizing harm to healthy cells and reducing toxicity. The use of this compound in combination with chemotherapy may be a promising strategy for treating cancer.
A series of Canadian studies found that conspicuous alcohol labels can increase awareness of drinking harms and guidelines, leading to a 6.9% decrease in total sales of alcohol. The labels provided information on the risks of alcohol consumption or drinking guidelines, improving knowledge of alcohol-related health risks such as cancer.
A large study of cancer patients with COVID-19 reveals a dramatically high case-fatality rate of 28%, significantly higher than the overall US mortality rate. The study emphasizes the importance of preventing cancer patients from contracting COVID-19 and closely monitoring for dangerous symptoms.
A new study by researchers from the University of Zurich and Harvard Medical School found that the high cost of cancer drugs in the US is not always justified. The study analyzed the costs of 65 cancer drugs in five countries and found no correlation between monthly treatment costs and clinical benefit.
A new form of local chemotherapy using a mitomycin-containing reverse thermal gel has been shown to be effective in treating low-grade upper tract urothelial cancer, allowing patients to keep their kidney. The treatment has a high complete response rate and is associated with manageable side effects.
A clinical trial found that a breast cancer drug called olaparib is more effective than targeted hormone therapy at keeping advanced prostate cancer in check. The study showed significant delays in disease progression for men with faulty DNA repair genes.
Scientists at Washington State University have discovered candidate genes that could be used to manufacture Taxol more quickly and efficiently. The genes, characterized by lead researcher Mark Lange, will enable engineers to develop organisms that can produce the cancer-fighting drug.
A University of Colorado Cancer Center study reveals significant variation in how drug side effects are reported, potentially leading to misinformation about a drug's safety. The study suggests standardizing reporting methods could improve the accuracy of risk assessments and drug licensing.
Patients receiving 177Lu-DOTATATE radiation therapy may experience travel delays at U.S. ports of entry due to residual radiation activity; carrying a travel card with treatment information can help alleviate this issue.
MIT engineers have devised a way to speed up drug development by rapidly testing how well drugs are absorbed in the small intestine. The new system uses pig intestinal tissue grown in the lab to test thousands of different versions of a drug in just hours.
A phase II randomized trial found that continuous dosing of BRAF and MEK inhibitors improved progression-free survival by nine months compared to intermittent treatment, which failed to show significant benefits. The study, led by the SWOG Cancer Research Network, enrolled 249 patients with common melanoma mutations and showed that con...
Researchers found that immunotherapy 'checkpoint' inhibitor treatment before surgery eliminated cancer evidence in nearly half of patients with Merkel cell carcinoma. The treatment approach may reduce surgery extent and slow tumor relapses.
Prolgolimab, a Russian original PD-1 inhibitor, has been approved for the treatment of advanced melanoma. The drug demonstrated significant antitumor activity and manageable safety in a phase II study, with 42 out of 126 patients experiencing an objective response.
Scientists have developed a multi-functional graphene-based nanomedicine that targets cancer cells with enhanced anticancer activity. The material, which combines three types of molecules for improved tumor targeting and drug delivery, shows promise for future biomedical applications.
A combination of immunotherapy agents encourages immune cells to consume tumors and alert others to attack, boosting survival for glioblastoma patients. The therapy, tested in a mouse model, successfully shrank tumors and extended life, with 55% of animals surviving over the course of the study.
A new AI model has been developed to classify colorectal polyps on histology slides with high accuracy, performing as well as practicing pathologists. The model was trained on a dataset from 24 different institutions and evaluated on an external dataset, demonstrating its generalizability.
A new targeted drug, adavosertib, has demonstrated strong activity against uterine serous carcinoma (USC), a hard-to-treat form of the disease. In nearly one-third of patients, tumors shrank in response to the treatment.
Metformin activates fat metabolism that promotes survival of dormant breast cancer cells during estrogen deprivation, suggesting context-dependent effects on cancer cells. This discovery informs ongoing clinical trials and guides the development of new therapeutic targets to selectively kill cancer cells.
Researchers have discovered a gene signature, USC73, that can identify women with rare and aggressive uterine serous carcinoma who are unlikely to respond to standard chemotherapy. The high USC73 score is associated with poor patient survival, cancer cell proliferation, and low rates of complete response to treatment.
A case series of lung cancer patients taking osimertinib (Tagrisso) revealed a rare twist in the right side of their colon, cecal volvulus. Doctors using this drug with EGFR+ non-small cell lung cancer patients should watch for these cases alongside more expected side effects.
A recent study published in Nature Cancer has revealed a critical pathway that regulates the production of PD-L1, a protein used by cancer cells to evade the immune system. By targeting this pathway, researchers hope to develop more effective cancer immunotherapies.
Researchers at Michigan Medicine and Case Comprehensive Cancer Center identified the binding site where drug compounds can activate a key braking mechanism against cancer. This discovery paves the way for developing new anti-cancer drugs that enhance tumor suppressor proteins.
A team of researchers used genome-wide CRISPR technology to identify RNA-binding proteins, including Staufen2, that sustain and protect drug-resistant leukemia stem cells. Loss of Staufen2 led to a reduction in leukemia growth and improved survival in mouse models.
A new strategy to overcome drug resistance in leukemia uses targeted doses of doxorubicin, inhibiting molecular pathways that promote tumor growth and resistance. Low-dose doxorubicin also stimulates the immune system, clearing the way for cancer-targeting immune cells to act.
A new study found that inhibiting the cancer drug resistance gene MDR1 can have unintended side effects on specialized immune system cells called CD8+ cytotoxic T lymphocytes. This could dull anti-cancer immune responses and increase vulnerability to infection. The research raises questions about the safety and utility of using systemi...
Researchers have discovered a new approach to overcome chemotherapy resistance in clear cell ovarian cancer by using low doses of 2-deoxy-D-glucose. The treatment has shown significant improvement in laboratory models and is expected to be safer for patients with reduced side effects.
The seven European cancer centers of Cancer Core Europe have shared their experiences and measures taken to adapt to the COVID-19 pandemic. They emphasize the importance of adapting clinical activities, communication with patients, qualified personnel, and regional collaborations to ensure continuity in cancer care.
Researchers at UCLA Jonsson Comprehensive Cancer Center identified a possible new drug, NSPP, that prevents cognitive decline in mice after radiation therapy for brain tumors. The study found the drug did not reduce radiation treatment efficacy.
Researchers at Lund University have developed a sensitive technique for delivering RNA molecules into cells, potentially opening up new avenues for treating cancer. The study uses cholesterol-linked siRNA and chloroquine to overcome the major obstacle of getting RNA molecules into the cell's cytosol.
Researchers at the Francis Crick Institute identified an experimental drug that prevents cancer from returning in mice. The drug, Quisinostat, works by increasing a protein called histone H1.0 within tumour cells, stopping them from replicating and growing.
A new study identifies key genes driving fibrolamellar carcinoma, a rare and deadly liver cancer. Researchers developed a cell model to test combination therapy strategies, including inhibitors of genes SLC16A14 and CA12, which showed promising results in killing tumor cells.
Researchers discovered that UM cells lacking the BAP1 protein activate mechanisms shutting down T lymphocytes, which are crucial immune cells fighting cancer. The study identified potential target molecules using existing drugs approved for other diseases, offering a promising approach to combat metastatic uveal melanoma.
Researchers at the University of Louisville are using the computing power of thousands of computers in classrooms across Kentucky to identify drugs to treat COVID-19. The DataseamGrid, a network of computers housed in classrooms, is being used to test over 11,000 drugs and compounds for potential effectiveness against SARS-CoV-2.
A study led by Washington State University researchers found that inhibiting the FOXO1 protein can protect the heart from cell death and atrophy caused by chemotherapy drugs like doxorubicin. This breakthrough discovery may lead to promising new treatment strategies or drugs that combine a FOXO1 inhibitor with doxorubicin.
Cancer drugs are detected in water systems due to human excretion and wastewater treatment facilities. Researchers urge proactive measures to identify potential gaps in knowledge regarding the consequences of anti-neoplastic exposure on aquatic organisms.
A Yale-led study found that a cancer therapy drug can slow T cell infiltration and reverse damage in kidney tissue damaged by lupus. The findings suggest the therapy might be beneficial for patients with lupus nephritis.
Daily marijuana users with severe pain reported worsening health over the past year, despite frequent cannabis use. The study found no association between marijuana use and changes in health status among those with low levels of pain.
A genetic variant in the MET gene has been identified as a driver of more aggressive growth in head and neck and lung cancers in Asians. The study suggests that targeting the variant may lead to improved disease outcomes through precision medicine.
A new study found that babies and young children with brain tumours tend to have better outcomes due to specific genetic weaknesses that can be targeted by existing drugs. Clinical trials are set to open to test the benefit of these precision medicines, offering a potential first-line treatment for infant brain tumours.
Researchers at the University of Virginia have identified inherited genetic variations that can predict patient outcomes and improve treatment success. By analyzing vast amounts of genetic data, doctors can now tailor treatments to individual patients' needs and genetic makeup.
A new report by global experts predicts that over 11 million children will die from cancer worldwide between 2020 and 2050 if no additional investment is made. However, the authors argue that sustainable care for children with cancer is affordable and achievable in all countries.
City of Hope researchers used lab-grown brain organoids to study the effects of cytomegalovirus on unborn babies, finding that a strain of HCMV can cause microcephaly by disrupting calcium signaling and brain development. The model could help identify potential therapies for the condition.
A new mouse model reveals that YAP activation exceeds a threshold for cancer development, suggesting a paradigm shift in understanding head-and-neck cancers. Inhibiting YAP may suppress cancer development and provide a target for treatments.
Engineers have developed a method to predict which mutations will occur in people, making it easier to create effective pharmaceuticals. The researchers used algorithms similar to those used in chemical physics to model how evolution works and found that biased random events play a big part in the evolution of resistance in leukemia.
A new case study using 5 head and neck squamous cell carcinoma cell lines shows improved drug screening through morphology and dead cell readouts. The research aims to enhance the value of cancer drug discovery and development success rates.
A recent study found that older cancer patients taking 15 or more medications prior to chemotherapy treatment had a 114% increase in hospitalization rates. The researchers also identified similar increases in breast and prostate cancer patients, with median medication counts of 6, 10, and 11 therapies respectively.
A new mass cytometry technique has identified key proteins in blood cancer cells, revealing why some cells are resistant to standard anti-cancer drugs. The research team hopes to apply this protocol to clinical trials to better understand why some cancers are resistant to therapies and match patients with more effective treatments.
Researchers at Texas A&M University have successfully harnessed bacteria's ability to create peptides with noncanonical amino acids, enabling the expansion of phage display libraries. This new method paves the way for new peptide-based therapeutics in cancer and other human diseases.
Death rates from metastatic melanoma dropped by nearly 18 percent between 2013 and 2016, thanks to new therapies that harness the immune system or target specific gene mutations. These advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded.
Researchers at Duke-NUS Medical School in Singapore have identified a common therapeutic vulnerability for a genetically diverse and deadly form of leukemia. The study reveals that the polycomb repressive complex plays a critical role in driving progression to blast crisis, a nearly always fatal stage of the disease.
Researchers used a combination of CTLA-4 and PD-1 blockers to shrink the size of the viral 'reservoir' in SIV-infected monkeys. The treatment showed promising results, but did not prevent or delay viral rebound once antiviral drugs were stopped.
The new drug Ru-Pt combines cisplatin, phenylbutyrate, and a PDT drug into one compound, increasing the chances of killing all cancer cells. It shows significant efficiency in killing cancer cells and has a ten times higher efficiency for drug-resistant cell lines than single reagents.
A drug delivery candidate technology has been approved by the FDA for human clinical trials to treat T-cell non-Hodgkin's lymphoma. The technology, developed with an NFCR grant, addresses the challenge of delivering a cancer-mitigating compound, fenretinide, in adequate doses to tumor cells.
Researchers at Johns Hopkins Medicine have discovered that statins can kill cancer cells by blocking the creation of a molecule necessary for their survival. The study suggests that statins may be valuable in combating certain types of cancer and could lead to new treatment options.
Researchers discovered that a combination of small molecules and CHK1 inhibitors can boost cancer cell killing, even in cancers resistant to current treatments. Targeting B-family DNA polymerases also increased effectiveness.
Researchers identified a potential intervention for triple-negative breast cancer by targeting the MYCN oncogene. Experimental drugs called BET inhibitors showed promise when combined with MEK inhibition in model systems overexpressing MYCN.